The Accelerated Molecule
Dr. Sophia Andersson
LeMay Publishing
HEALTHCARE
The Accelerated Molecule
Pharma Innovation9,784 words78 chapters
Published by LeMay Publishing. 9,784 words across 78 chapters.
About This Publication
A study of adaptive trials, computational discovery, and the transformation of pharmaceutical development, examining how the industry's temporal paradox of urgency and delay is being resolved through technological acceleration.
Published by LeMay Publishing, a division of LeMay. Massachusetts.
ISBN: 979-8-0000-7025-3
Chapters
1THE ACCELERATED MOLECULE
2Adaptive Trials, Computational Discovery, and the Transformation of Pharmaceutical Development
3ABOUT THE AUTHOR
4TABLE OF CONTENTS
5PREFACE
6CHAPTER 1
7The Imperative of Acceleration: Why Speed Became Survival
81.1 The Historical Burden of Pharmaceutical Time
91.2 The Accumulation of Inefficiency
101.3 The Catalysts of Change
111.4 The Architecture of This Inquiry
12CHAPTER 2
13Computational Drug Discovery: From In Silico Screening to Generative Molecular Design
142.1 The Computational Turn
152.2 Structure-Based and Ligand-Based Approaches
162.3 Generative Molecular Design
172.4 The AlphaFold Revolution and Its Downstream Consequences
182.5 Limitations and the Experimental Imperative
19CHAPTER 3
20Adaptive Clinical Trials: Redesigning the Architecture of Evidence
213.1 The Limitations of Fixed Design
223.2 The Adaptive Paradigm
233.3 Bayesian Frameworks and Adaptive Design
243.4 Master Protocols: Basket, Umbrella, and Platform Trials
253.5 Seamless Phase Designs
263.6 Regulatory Acceptance and Remaining Challenges
27CHAPTER 4
28Biomarkers and Precision Endpoints: Sharpening the Tools of Measurement
294.1 The Endpoint Problem
304.2 Surrogate Endpoints and Accelerated Approval
314.3 Predictive Biomarkers and Population Enrichment
324.4 Digital Biomarkers and Continuous Monitoring
334.5 Composite and Multi-Modal Endpoints
34CHAPTER 5
35Regulatory Science in Transition: Accelerated Pathways and Real-World Evidence
365.1 The Evolution of Accelerated Regulatory Pathways
375.2 Rolling Submissions and Real-Time Review
385.3 Real-World Evidence and Post-Market Commitments
395.4 International Regulatory Harmonization
40CHAPTER 6
41Artificial Intelligence and Machine Learning in the Development Pipeline
426.1 The Scope of AI Application
436.2 Target Identification and Validation
446.3 Clinical Trial Optimization
456.4 Natural Language Processing and Regulatory Intelligence
466.5 Pharmacovigilance and Safety Monitoring
47CHAPTER 7
48Platform Technologies and Rapid-Response Pharmacology
497.1 The Platform Concept
507.2 mRNA Platforms
517.3 Antibody Platforms
527.4 Cell and Gene Therapy Platforms
537.5 Pandemic Preparedness and Rapid-Response Frameworks
54CHAPTER 8
55Manufacturing at the Speed of Discovery: Continuous Processing and Digital Quality
568.1 The Manufacturing Bottleneck
578.2 Continuous Manufacturing
588.3 Process Analytical Technology and Real-Time Release
598.4 Digital Twins and Predictive Manufacturing
608.5 Decentralized and Modular Manufacturing
61CHAPTER 9
62Economic and Ethical Dimensions of Accelerated Development
639.1 The Economics of Speed
649.2 The Cost of Failure
659.3 Access and Equity
669.4 The Ethics of Incomplete Evidence
679.5 Patient Centrality
68CHAPTER 10
69The Future Molecule: Convergence, Integration, and the Next Pharmaceutical Paradigm
7010.1 The Convergent Trajectory
7110.2 The Digital Thread
7210.3 Autonomous and Semi-Autonomous Laboratories
7310.4 Individualized Therapeutics and N-of-1 Development
7410.5 Quantum Computing and the Next Computational Frontier
7510.6 The Institutional Imperative
7610.7 Closing Reflection
77BIBLIOGRAPHY
78INDEX